Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah because it was cancelled due to covid-19 but you knew that.
Bunyaviruses and Alphaviruses next possibly Monkeypox testing?
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
It was unfortunate during that period the shut down lead to symposium being canceled but covid-19 is what got us here.
Like I said B seen as a broad spectrum countermeasure. A military contract would be fantastic.
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses
B seen as a broad spectrum countermeasure. A military contract would be fantastic.
Yep a good one absolutely :)
Squalus Medical Business & Industrial Park Caesarea, Haifa, Israel
6 days ago 32 applicants
Wow 32 applicants.
Thread originally posted by PJ007 . Have to ask him, nice buy though.
Post# 389394 Thursday, April 21, 2022 6:47:28 PM
Again, i purchased 100k today and it shows up as a sell.....why is that....
Hmm up over 50% pretty smart move for the buyer:)
Well. In my opinion if one is dumb enough to attempt to buy 100k shares of IPIX today, they might have been dumb enough to click sell instead of buy.
Exactly we are in a different dynamic now as news can come from multiple sources. Here at home I believe OM is next up.
Ditto!
B the great inhibitor. Go Rutgers and GMU.
I've been buying and glad of it.
Clearly the government likes results they are seeing in B "On March 7, 2022, the Company also noted that collaborative research with National Institutes of Health (NIH) and other scientists remains ongoing. Brilacidin’s broad-spectrum in vitro antiviral activity is generating positive data, including results showing Brilacidin is potent against the Alpha, Gamma and Delta variants of SARS-CoV-2, with publications and conference abstracts related to this research in process of preparation".
Agree. The following was from early December so likely it was already in the works. Now we have the Fox chase agreement and this new asset investment deal. Leo said agreements so I would imagine OM would be next.
"Elsewhere, Innovation management is engaged in discussions potentially to acquire rights to new pipeline assets, as well as to enter into new licensing agreements."
I'm pretty excited about IPIX future because after all B is still being tested by government labs. Really though at this point in time what investment isn't at risk.
On May 3, 2022, the Company was notified it would receive payment from FCCDC based on FCCDC’s third-party license of broad-spectrum anti-fungals and a separate agreement between Innovation and FCCDC. Some of the preliminary data used in the FCCDC research program had been obtained as part of an earlier collaboration with the Company supported by funding from the National Institutes of Health.
On March 7, 2022, the Company also noted that collaborative research with National Institutes of Health (NIH) and other scientists remains ongoing. Brilacidin’s broad-spectrum in vitro antiviral activity is generating positive data, including results showing Brilacidin is potent against the Alpha, Gamma and Delta variants of SARS-CoV-2, with publications and conference abstracts related to this research in process of preparation.
Yeah. More of an investment then asset. Hope now we see a B deal.
I don't have an answer but from my reading without personally knowing the ownership it would be difficult.
Per new 8k- Item 1.01 Entry into a Material Definitive Agreement.
On June 9, 2022, Innovation Pharmaceuticals Inc. (the “Company”) entered into a Series A Preferred Share Purchase Agreement (the “Purchase Agreement”) with Squalus Med Ltd., a company established under the laws of the State of Israel (“SML”), pursuant to which the Company purchased 55,556 shares of SML’s Series A Redeemable Preferred Shares (the “Series A Shares”) and a warrant (the “Warrant”) to purchase 27,778 Series A Shares for aggregate consideration of $4,000,000, or approximately $72.00 per Series A Share. Following the closing under the Purchase Agreement, the Company owns approximately 35.7% of SML’s issued and outstanding equity securities and approximately 41.6% of SML’s equity securities on a fully diluted basis. The Company also entered into customary investor rights and indemnification agreements with SML.
So IPIX has a sizeable stake.
Yes that would be good to know but so far no announcement.
Squalus to pursue the FDA 510(k) pathway for marketing clearance in the U.S. and the corresponding process for a CE Mark in Europe
Good move and as a device shorter approval process.
Wake up the whole market is being scorched. At this price this can be the one that makes money.
Another avenue is a license deal to further develop B in an intranasal form-
"The Company also plans to seek additional clinical development support from the NIH Antiviral Program for Pandemics (APP). Brilacidin for prophylactic use, including assessing Brilacidin in pre-clinical animal models, is of particular interest due to Brilacidin's blocking and neutralizing antiviral properties and industry investment in developing intranasal-targeted, direct-acting antivirals.
Preliminary Brilacidin formulation work for inhaled delivery has been conducted, with the NIH APP a potential avenue to expand on this work, along with exploring the subcutaneous administration of Brilacidin, which has greater than 70 percent bioavailability via this route of administration."
Oh yeah. Good to see you back.
Agree. Leo's not even pumping fluff.
Looking forward to the next round of news.
Right along with you.
It’s no wonder FDA advised IPIX to dial down the dose in the COVID 19 study.
Definitely been a long quiet period. I'm anticipating good news at the end of it we need it.
With all the deals that Leo is working on
Brilacidin is listed as a key product.
Some say he's selling, I'm thinking merger. Leo's gone quiet so there's no direction either way so who knows. Leo had said they were looking into acquiring other assets the only way I see that happening is with another company coming in. The so called analysis is a way of saying we are estimating our drugs worth in dollars. Hopefully things are closer then they appear.
As of March 31, 2022, the Company has largely paused clinical development to strategically analyze all the scientific data collected to date across its portfolio of assets. Drug manufacturing, scientific report writing, and supportive research activities continue. While the analysis is performed, management is focused on other avenues of business development, including, but not limited to, joint ventures, mergers and acquisitions, strategic investments, and licensing agreements, for the purpose of diversifying corporate assets.
Basilea pharma which is located in Basel and then we see a direct connection to Brilacidin in that Edison group report. Good to see this frenchbroad.
When looking at all the wording as a whole it sounds more like a merger.
It means things in Europe are getting back to normal. Good to see the Alpha trial progress.
On March 7, 2022, the Company also noted that collaborative research with National Institutes of Health (NIH) and other scientists remains ongoing. Brilacidin’s broad-spectrum in vitro antiviral activity is generating positive data, including results showing Brilacidin is potent against the Alpha, Gamma and Delta variants of SARS-CoV-2, with publications and conference abstracts related to this research in process of preparation.
Given the promising treatment effects observed with Brilacidin in treatment of COVID-19 (from the Phase 2 clinical trial and compassionate use cases), combined with the broad-spectrum in vitro antiviral data, the Company plans to submit Brilacidin to government-sponsored platforms for possible inclusion in clinical trials and additional development funding support.
That's the second new employee.
On March 7, 2022, the Company reported further findings from the Phase 2 COVID-19 clinical trial and compassionate use of Brilacidin in critically-ill COVID-19 patients
In the Phase 2 clinical trial, beneficial Brilacidin treatment effects were observed on National Early Warning Score 2 (NEWS2) secondary endpoints, as well as on the primary endpoint for patient subgroups (with most elevated biomarker/viral load levels). For this study population, early treatment with Brilacidin from onset of symptoms appeared to have a positive impact on time to sustained recovery: if a patient started study treatment within fewer than 7 days of onset of COVID-19 symptoms, patients in the Brilacidin 5-dose group achieved sustained recovery more quickly compared to the pooled placebo group (p=0.03).
From compassionate use of Brilacidin in critically-ill COVID-19 patients, noticeable treatment effects attributed to the use of Brilacidin were reported by investigators. Patients receiving compassionate use of Brilacidin were at advanced stages of disease and had exhausted other conventional treatment options. Compassionate use cases comprised Brilacidin being administered to critically-ill COVID?19 patients over a longer duration (up to 10 days of treatment) than in the Phase 2 COVID-19 clinical trial (3 and 5 day dosing), with some patients also receiving higher and more frequent (twice daily) dosing. There appeared to be a potentially favorable treatment response based on increased Brilacidin dosing. For the Brilacidin compassionate use cases, in general, investigators observed more stable disease with initial improvements evident on chest x-rays and in COVID-19 disease biomarkers (e.g., C-Reactive Protein and ferritin). While nearly all of these critically-ill patients ultimately succumbed to severe hypoxic respiratory failure (secondary to COVID-19 viral pneumonia) and expired, survival time for these patients who initially were not expected to live beyond a few days was appreciably extended.
Good to see lives were extended with B.
I agree somethings afoot. Definitely been quiet.
Only recently has Basilea come on the MRSA and ABSSSI scene. New company building a antibiotic pipeline. Brilacidn in Basilea articles is nice to see. Maybe something or not but there is interest or it wouldn't be in there.